Kailiwei® is the commercial brand name of Coblopasvir Hydrochloride Capsules, a hepatitis C virus non-structural protein 5A (NS5A) inhibitor. It binds to HCV NS5A protein to block viral replication and virion assembly.
Main Indications
In combination with other antiviral medicines, for the treatment of adult patients with chronic hepatitis C virus (HCV) infection.
Clinical Research
Clinical studies demonstrated that coblopasvir-containing regimens achieved high SVR12 rates for HCV genotype 1, 2, 3, 6 infections. It retains antiviral activity against many resistance-associated variants. The combination therapy shows good tolerability and a short treatment duration for eligible patients.
Common Side Effects
Systemic reactions: headache, fatigue;
Common mild adverse reactions: nausea, diarrhea, insomnia. Rare serious adverse events: severe liver injury, hypersensitivity reactions.
Approval Status in China
Original drug Kailiwei® (Coblopasvir Hydrochloride Capsules) was officially approved for marketing in China in 2020, with the specification of 100mg. It is currently a prescription antiviral drug.
Buy Kailiwei (Coblopasvir Hydrochloride Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
